ABCM Key Statistics, Chart & Performance
The current stock price of ABCM is 23.99 USD. In the past month the price increased by 3.05%. In the past year, price increased by 54.57%.
ABCM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 387.19B | ||
| AMGN | AMGEN INC | 14.75 | 173.65B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 151.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.19 | 115.35B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.81 | 79.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 723.35 | 48.74B | ||
| INSM | INSMED INC | N/A | 34.70B | ||
| NTRA | NATERA INC | N/A | 32.40B | ||
| BIIB | BIOGEN INC | 10.78 | 26.48B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.98B | ||
| INCY | INCYTE CORP | 16.33 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.01 | 20.46B |
Related stock screener links
About ABCM
Company Profile
Abcam Plc is a global life science company, which distributes antibodies and associated protein research tools. The company is headquartered in Cambridge, Cambridgeshire and currently employs 1,750 full-time employees. The company went IPO on 2005-11-03. The firm is engaged in the identification, development and distribution of biological reagents. The Company’s products are used by various researchers worldwide to study biological pathways critical for scientific research, diagnostics and drug discovery. Its products can be grouped into two categories: research use only (RUO) proteomic tools and antibodies for clinical application. RUO products include protein binding reagents, such as antibodies and immunoassays, and related reagents. Its RUO products are used to detect, quantify, visualize and modify proteins in scientific research experiments, serving as vital tools to enable its customers to develop insights about targets and biological pathways of interest. Antibodies are a core component of many in vitro diagnostic assays and can also be used as therapeutic agents to treat various diseases, including cancer.
Company Info
ABCAM PLC-SPON ADR
Discovery Drive, Cambridge Biomedical Campus, Hills Road
Cambridge CAMBRIDGESHIRE CB2 0AX GB
CEO: Alan Hirzel
Employees: 1750
Phone: 441223696000.0
ABCAM PLC-SPON ADR / ABCM FAQ
Can you describe the business of ABCAM PLC-SPON ADR?
Abcam Plc is a global life science company, which distributes antibodies and associated protein research tools. The company is headquartered in Cambridge, Cambridgeshire and currently employs 1,750 full-time employees. The company went IPO on 2005-11-03. The firm is engaged in the identification, development and distribution of biological reagents. The Company’s products are used by various researchers worldwide to study biological pathways critical for scientific research, diagnostics and drug discovery. Its products can be grouped into two categories: research use only (RUO) proteomic tools and antibodies for clinical application. RUO products include protein binding reagents, such as antibodies and immunoassays, and related reagents. Its RUO products are used to detect, quantify, visualize and modify proteins in scientific research experiments, serving as vital tools to enable its customers to develop insights about targets and biological pathways of interest. Antibodies are a core component of many in vitro diagnostic assays and can also be used as therapeutic agents to treat various diseases, including cancer.
Can you provide the latest stock price for ABCAM PLC-SPON ADR?
The current stock price of ABCM is 23.99 USD. The price increased by 0.04% in the last trading session.
Does ABCM stock pay dividends?
ABCM does not pay a dividend.
What is the ChartMill rating of ABCAM PLC-SPON ADR stock?
ABCM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for ABCAM PLC-SPON ADR?
ABCAM PLC-SPON ADR (ABCM) operates in the Health Care sector and the Biotechnology industry.
Who owns ABCAM PLC-SPON ADR?
You can find the ownership structure of ABCAM PLC-SPON ADR (ABCM) on the Ownership tab.
ABCM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ABCM. When comparing the yearly performance of all stocks, ABCM is one of the better performing stocks in the market, outperforming 89.33% of all stocks.
ABCM Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ABCM. ABCM scores excellent on profitability, but there are some minor concerns on its financial health.
ABCM Financial Highlights
Over the last trailing twelve months ABCM reported a non-GAAP Earnings per Share(EPS) of 0.54. The EPS increased by 402.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.94% | ||
| ROA | 0.64% | ||
| ROE | 0.93% | ||
| Debt/Equity | 0.3 |
ABCM Forecast & Estimates
15 analysts have analysed ABCM and the average price target is 20.23 USD. This implies a price decrease of -15.68% is expected in the next year compared to the current price of 23.99.
For the next year, analysts expect an EPS growth of 125.95% and a revenue growth 24.37% for ABCM